The launch of a strategic initiative by Actinium Pharmaceuticals to focus on the manufacture of Actinium-225 (Ac-225) is likely to have a positive impact on its stock price in the short term. This is because Ac-225 is highly sought after for its use in targeted alpha therapy for cancer treatment, and positioning the company as a key supplier could significantly enhance its market presence and revenue potential. The initiative demonstrates the company's commitment to innovation and addressing critical needs in cancer therapy, which could attract positive investor sentiment.